|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0032790,
umls-concept:C0034656,
umls-concept:C0087111,
umls-concept:C0205225,
umls-concept:C0205420,
umls-concept:C0205539,
umls-concept:C0684224,
umls-concept:C0746319,
umls-concept:C1516238,
umls-concept:C1521750,
umls-concept:C1522673,
umls-concept:C1705294
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2003-4-16
|
|
pubmed:abstractText |
Using a 2 x 2 factorial design, we studied the adjuvant chemotherapy of women with axillary node-positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) with concurrent doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) for disease-free (DFS) and overall survival (OS); to determine whether the dose density of the agents improves DFS and OS; and to compare toxicities.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AbramsJeffreyJ,
pubmed-author:BerryDonald ADA,
pubmed-author:CarpenterJohnJ,
pubmed-author:CirrincioneConstanceC,
pubmed-author:CitronMarc LML,
pubmed-author:DavidsonNancy ENE,
pubmed-author:GradisharWilliam JWJ,
pubmed-author:HollandJames FJF,
pubmed-author:HudisCliffordC,
pubmed-author:HurdDavidD,
pubmed-author:IngleJames NJN,
pubmed-author:LeungEleanor HEH,
pubmed-author:LivingstonRobertR,
pubmed-author:MartinoSilvanaS,
pubmed-author:MussHyman BHB,
pubmed-author:NortonLarryL,
pubmed-author:PerezEdith AEA,
pubmed-author:SartorCarolyn ICI,
pubmed-author:SchilskyRichard LRL,
pubmed-author:SmithBarbara LBL,
pubmed-author:WinerEric PEP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1431-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12668651-Adult,
pubmed-meshheading:12668651-Aged,
pubmed-meshheading:12668651-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12668651-Breast Neoplasms,
pubmed-meshheading:12668651-Chemotherapy, Adjuvant,
pubmed-meshheading:12668651-Cyclophosphamide,
pubmed-meshheading:12668651-Doxorubicin,
pubmed-meshheading:12668651-Drug Administration Schedule,
pubmed-meshheading:12668651-Female,
pubmed-meshheading:12668651-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:12668651-Humans,
pubmed-meshheading:12668651-Middle Aged,
pubmed-meshheading:12668651-Multivariate Analysis,
pubmed-meshheading:12668651-Paclitaxel,
pubmed-meshheading:12668651-Proportional Hazards Models,
pubmed-meshheading:12668651-Recombinant Proteins,
pubmed-meshheading:12668651-Survival Analysis,
pubmed-meshheading:12668651-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
|
|
pubmed:affiliation |
ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA. mcitron@prohealthcare.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
